July - 2017

The Coalition to

Protect Patient Choice

A Project

of the

Law Offices

of David Balto

Competitive healthcare is healthcare with choices

Advocacy on consumer healthcare competition issues aimed at lowering prescription drug costs

Senate Votes Against Repeal of Affordable Care Act

Senate Votes Against Repeal of Affordable Care Act

In the very early hours of the morning, the Senate voted against a scaled-back plan to repeal sections of the Affordable Care Act. By a vote of 49-51, the Senate did not pass the bill. All Democratic Senators voted against the plan, and three Republicans--Lisa Murkowski of Alaska, Susan Collins of Maine, and John McCain of Arizona--joined them. This is a significant setback to Senate Majority Leader Mitch McConnell's efforts to get rid of the ACA; this week he has attempted t

House Subcommittee Holds Hearing on Generic Drug Access and FDA Abuses, Praises CREATES Act

House Subcommittee Holds Hearing on Generic Drug Access and FDA Abuses, Praises CREATES Act

Yesterday afternoon the House Subcommittee on Regulatory Reform, Commercial, and Antitrust Law held a hearing on antitrust concerns, the FDA’s approval process for generic drugs, and how it impacts access to generic drugs. Both Democrat and Republican members agreed that abuses of the regulatory process were a serious problem and endorsed the CREATES Act to stop these abuses. The hearing demonstrated that the CREATES Act enjoys bipartisan support, and that there is an opportu

Democrats Unveil Sweeping New Antitrust and Drug Price Proposals

Democrats Unveil Sweeping New Antitrust and Drug Price Proposals

Earlier today Senator Minority Leader Chuck Schumer (D-NY) and House Minority Leader Nancy Pelosi announced several new proposals to stop corporate consolidation and reduce prescription drug prices. These proposals go beyond what congressional leaders have endorsed in the past, and signify that they are willing to make sweeping changes to protect consumers and deal with these problems. The first proposal focuses on rising prescription drug prices. It bluntly states that our c

FDA Regulatory Abuses and How to Solve Them: REMS, Citizen Petitions, and Product Hopping

FDA Regulatory Abuses and How to Solve Them: REMS, Citizen Petitions, and Product Hopping

The Food and Drug Administration's recent public meeting demonstrated that brand companies are engaging in wide-spread abuse of regulations in order to block access to generic drugs. As Mr. Balto said in his presentation, predation by abuse of government procedure is one of the most insidious anticompetitive practices. He covered three of the most egregious abuses in his presentation and offered possible solutions for them; below are short summaries of the main problems. The

Repealing the Affordable Care Act Is A Bad Idea. Congress Should Instead Focus on Reducing Drug Pric

Repealing the Affordable Care Act Is A Bad Idea. Congress Should Instead Focus on Reducing Drug Pric

The proposed Senate healthcare bill has failed, but another bad idea has risen to take its place. Recent reports show that the Senate will soon consider just repealing the Affordable Care Act, without have any replacement healthcare bill, and that a vote on this will take place early next week. This idea is a terrible one that will harm tens of millions of Americans. Congress should reject the proposal and instead focus on enacting legislation to reduce out-of-control drug pr

FDA Public Meeting Examines Regulatory Abuse and Generic Drug Access

FDA Public Meeting Examines Regulatory Abuse and Generic Drug Access

Yesterday, July 18th, the Food and Drug Administration held a very large public meeting at their White Oak campus in Silver Spring to get public input on the Hatch-Waxman amendments and access to generic drugs. Many different individuals and organizations testified that brand drug companies are abusing FDA regulations to delay or block access to generic drugs, and called for action to end these abuses. The three areas are the misuse of REMS protocols, the abuse of citizen pet

Connecticut Enacts Law to Stop PBM Clawbacks

Connecticut Enacts Law to Stop PBM Clawbacks

This Monday, July 10th, Connecticut Governor Dan Malloy signed a bill to close an important drug price loophole and stop an abusive practice by pharmacy benefit managers (PBMs) known as clawbacks. The bill allows pharmacists to tell patients about the cheapest ways to pay for prescription drugs they pick up at the pharmacy. PBMs often use their power to negotiate contracts with pharmacists that prohibit drugstores from telling their patients about cheaper prices. A 'clawback'

Louisiana Health Secretary Facing Public Health Crisis Due to Expensive Medicines

Louisiana Health Secretary Facing Public Health Crisis Due to Expensive Medicines

Parts of Louisiana have the worst public health outcomes in the United States. There are two main contributors to this problem: poverty and poor health, leading to high rates of obesity, premature births, and high rates of Hepatitis C, a liver-damaging virus often gotten by drug uses. Hepatitis C can cause cirrhosis and cancer, but several new medicines can cure this disease. However, these drugs are so expensive that Louisiana Health Secretary Rebekah Gee is considering a ra

Featured Posts

United States-Mexico-Canada Agreement (USMCA)

United States-Mexico-Canada Agreement (USMCA)

Congress Bans Gag-Clauses on Pharmacists

Congress Bans Gag-Clauses on Pharmacists

Letter from David A. Balto on behalf of Consumer Action and CPPC to the Federal Trade Commission, re

Letter from David A. Balto on behalf of Consumer Action and CPPC to the Federal Trade Commission, re

The Promise of Biosimilars

The Promise of Biosimilars

Recent Posts

Archive

Search By Tags

No tags yet.

Follow Us